Age-Corrected Beta Cell Mass Following Onset of Type 1 Diabetes Mellitus Correlates with Plasma C-Peptide in Humans

It's Time to Consider Changing the Rules: The Rationale for Rethinking Control Groups in Clinical Trials Aimed at Reversing Type 1 Diabetes

(2011) M. A. Atkinson   DIABETES

Type 1 Diabetes Immunotherapy: Is the Glass Half Empty or Half Full?

(2011) K. C. Herold et al.   Science Translational Medicine

What are the Potential Benefits of Clinical β-Cell Imaging in Diabetes Mellitus?

(2010) Burkhard Goke   CURRENT PHARMACEUTICAL DESIGN

An empirical Bayesian approach for model-based inference of cellular signaling networks

(2009) David J Klinke   BMC BIOINFORMATICS

Functional Assessment of Pancreatic  -Cell Area in Humans

(2009) J. J. Meier et al.   DIABETES

Modulating Temporal Control of NF-κB Activation: Implications for Therapeutic and Assay Selection

(2008) David J. Klinke et al.   BIOPHYSICAL JOURNAL

Economic Costs of Diabetes in the U.S. in 2007

(2008)   DIABETES CARE

Extent of Beta Cell Destruction Is Important but Insufficient to Predict the Onset of Type 1 Diabetes Mellitus

(2008) David J. Klinke   PLoS One